Hence, a priori selecting patients with a history of MDD that is resistant to treatment (with a matched healthy control group at baseline) may help to determine how dysregulation of the HPA axis (including oxytocin) relates to the pathophysiology of symptoms experienced by certain patients, and whether the HPA axis may represent a clinically relevant treatment target. This evidence concerns the gene OXT and major depressive disorder.